🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Phase 1 data of the EGFRxHER3 bispecific ADC Iza-Bren for HER2- MBC. Iza-Bren has a similar target, linker, payload & DAR c/w HER3-DXd, and showed activity comparable to HER3-DXd (ORR 44%, mPFS 6.9 months), but higher hematologic toxicity & stomatitis. Payload innovation needed!

From ESMO - Eur. Oncology YOC we want to thank Sherene Loi, MD Peter Dubsky MarleenKokLab for a captivating and inspiring mentorship session yesterday #ESMOBreast25 Rodrigo Sánchez-Bayona Angelika Starzer

A great pleasure to meet in-person for the first time with Maria Illia whom I had the privilege to exchange with via the ESMO - Eur. Oncology Virtual Mentorship Program. Maria has a keen interest in developing research projects and is dedicating time to that on top of her clinical work 👏

Take home messages of a comprehensive overview on response and toxicity prediction biomarkers in ADC G Curigliano MD PhD ✅Few currently available biomarkers to guide selection ✅ A growing list of potential markers ✅ Need of Mechanisms to Discover and Validate biomarkers #ESMOBreast25

How to currently treat patients with progression on ADCs according to Javier Cortes MD PhD #ESMOBreast25 #ESMOAmbassadors ESMO - Eur. Oncology

#ESMOBreast25 translational research highlights and what to in clinic tomorrow! ESMO - Eur. Oncology #ESMOAmbassadors

As the #oncology field evolves, ESMO is keeping pace - regularly ensuring its tools reflect the latest in #ClinicalEvidence and regulatory shifts. An important evolution is just around the corner — keep an eye out. #ESMOMCBS

Live from #ESMOBreastBCY…just got a couple of very precious gifts from my mentor & hero Ann Partridge MD, MPH ❤️ GRAZIE MILLE for what you have done for young #BreastCancer community & #oncology fellows !!! ESMO - Eur. Oncology OncoAlert #ESMOBreast25 #ESMOambassadors Dana-Farber’s Breast Oncology Center Dana-Farber

Excelente charla y panel de discusión sobre el manejo de pacientes jóvenes con cáncer de mama portadoras de variantes patogénicas en gBRCA1/2. Un cierre de congreso excepcional 👏 Pablo Mando #SuzetteDelaloge #GiuseppeCurigliano #PeterDubsky #IcroMeattini Matteo Lambertini, MD PhD

AAOC JOVEN EN ESMO BREAST Dos integrantes del Comité Joven de la Asociación Argentina de Oncología Clínica, la Dra. María Illia (CEMIC) y la Dra. Cielo Elaskar (COIR Mendoza) estuvieron presentes, en ESMO Breast, representando a Argentina y al talento joven en Oncología.

It’s been an honor and privilege to have been part of the faculty of BCY at #ESMOBreast25 A growing community working for the young patients with BC. Thank you Matteo Lambertini, MD PhD and Dr Paluch-Shimon 👏👏👏 Ann Partridge MD, MPH Kevin Kalinsky, MD, MS, FASCO Peter Dubsky Rebecca Dent Icro Meattini

#ASCO25 abstracts are out! INAVO120: HR+ MBC, PIK3CA-mut Inavolisib + palbo + fulv vs placebo combo: - OS: 34 vs 27 m (HR 0.67, 95% CI 0.50–0.91) - PFS: 17.2 vs 7.3 m - ORR: 62.7% vs 28% - Time to chemo: 35.6 vs 12.6 m ⚠️ Hyperglycemia (any grade): 63.4% vs 13.5% OncoAlert

AI improved pathogists’ concordance in HER2 determination #ASCO2025

Promising activity of Sac-TMT as 1L treatment for patients with mTNBC: ⚪️ORR 70.7% ⚪️mDoR 12.2 mo ⚪️mPFS 13.4 mo ⚪️ 12-mo PFS rate 64.6%. #ASCO2025

Interesting data of co-inhibition of Her2 and PIK3CA in heavly pretreated patients #ASCO2025

As always Ines Vaz Luis gives a profound lecture on the potential of eHealth solutions for therapy management and follow up care. Highlighting the need for: ▪️Coordinated care ▪️Patient empowerment ▪️Robust digital infrastructure #ASCO2025

Vepdegestrant (oral PROTAC) demonstrated significant improvement in PFS in patients with ESR 1m ER+/HER2- mBC and a favorable safety profile. A new kid in the block after CDKi PD. A question is if Fulvestrant monotherapy is the proper control arm #ASCO2025 Erika Hamilton, MD

Inavolisib addition to Palbociclib + Fulvestrant improved OS (34m vs 27m), PFS (17m vs 7m), ORR (62% vs 28%) and DOR (19m vs 11m) in a poor risk population. Impressive delay to first subsequent CT of almost 2y!!! #ASCO2025

Oral paclitaxel is here. Now lets work to give access to our patients to another oral chemotherapy option! #ASCO2025

In DB06 biomarker-evaluable population, there was a potentially greater efficacy benefit with T-DXd in the BRCA1/2 mutation subgroup (albeit with a small sample size). Biological rationale??? #ASCO2025 Rebecca Dent